 Pharmaceutical firm Veru NASDAQ: VERU kicked off the first complete week of November with a bang as it delivered overall positive results regarding its Covid-19 therapeutic sabizabulin. Targeting the treatment of Covid-19 for hospitalized patients at high risk of acute respiratory distress syndrome ARDS, sabizabulin demonstrated effectiveness at reducing the death rate in a late-stage trial. 